Pathway candidateNCBI-verifiedprotein-coding

PPARG

peroxisome proliferator activated receptor gamma

NCBI Gene: 5468 Ensembl GeneCards UniProt: P37231

Pathway candidate — not linked to PFS or PSSD by any record here

PPARG is in the library because it belongs to the nuclear receptors family. No study, report or commentary in the corpus names it, so a variant in PPARG is not, by itself, evidence of anything related to post-drug syndromes.

Gene summary

A protein-coding gene on chromosome 3 (steroid and nuclear hormone receptors). Encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes.

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Peroxisome proliferator-activated receptor gamma
Function (excerpt): Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids. Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metabolites. Ligand-binding results in a conformational change in the receptor, promoting dissociation of repressors and recruitment of coactivators, and subsequent activation of target gene expression. Specifically binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase (By similarity). Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated pro-inflammatory responses.
Subcellular location: Nucleus; Cytoplasm.
Tissue specificity: Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.
Associated conditions: Obesity (OBESITY); Lipodystrophy, familial partial, 3 (FPLD3); Glioma 1 (GLM1).

Source: UniProtKB/Swiss-Prot P37231, release 2026_03, licensed CC BY 4.0. This is the protein’s normal biology, not evidence about post-drug syndromes; associated conditions are inherited disorders of the gene, not PFS, PSSD or PRSD.

Why its pathway is in the library

Nuclear receptors transduce steroid signals into lasting gene-expression programs; persistent receptor-level remodeling (or silencing) is a leading hypothesis for symptoms that outlast drug exposure.

Written for the whole nuclear receptors family, not for PPARG specifically.

Mentioned in 0 corpus records

No corpus record names PPARG directly yet. It is in the library because it sits in a pathway the corpus tracks (Nuclear receptors).

Also in steroid and nuclear hormone receptors

All 41 genes

Browse by family on the gene families page.

Gene summary

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Peroxisome proliferator-activated receptor gamma
Function (excerpt): Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids. Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metabolites. Ligand-binding results in a conformational change in the receptor, promoting dissociation of repressors and recruitment of coactivators, and subsequent activation of target gene expression. Specifically binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase (By similarity). Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated pro-inflammatory responses.
Subcellular location: Nucleus; Cytoplasm.
Tissue specificity: Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.
Associated conditions: Obesity (OBESITY); Lipodystrophy, familial partial, 3 (FPLD3); Glioma 1 (GLM1).